Crit Care Med:输注红细胞,对失血性休克患者的舌下微循环有什么影响?

2016-10-15 MedSci MedSci原创

红细胞输注对微血管灌注的影响并没有得到很好的研究。我们对失血性休克患者进行了本项前瞻性、初步观察研究,评估红细胞输注对舌下微循环的影响。 研究地点为一所大学医院里28张床的外科重症监护病房。纳入了15例失血性休克患者,需要红细胞输注。研究干预为一个单位的红细胞输注。 在红细胞输注前后,使用侧流暗场成像装置评估患者的舌下微循环情况。输注一个单位的红细胞后,血红蛋白浓度从8.5 g/dL

红细胞输注对微血管灌注的影响并没有得到很好的研究。我们对失血性休克患者进行了本项前瞻性、初步观察研究,评估红细胞输注对舌下微循环的影响。

研究地点为一所大学医院里28张床的外科重症监护病房。纳入了15例失血性休克患者,需要红细胞输注。研究干预为一个单位的红细胞输注。

在红细胞输注前后,使用侧流暗场成像装置评估患者的舌下微循环情况。输注一个单位的红细胞后,血红蛋白浓度从8.5 g/dL (7.6-9.5 g/dL)增加至9.6 g/dL (9.1-10.3 g/dL) g/dL (p = 0.02),但是对大循环参数(动脉压、心脏指数、心率和脉压变化)没有影响。

输注红细胞可显著增加微循环血流指数(从2.3 [1.6-2.5]到2.7 [2.6-2.9]; p < 0.003)、灌注血管比例(从79% [57-88%]到92% [88-97%]; p < 0.004)和毛细血管密度(从21 [19-22]到24 [22-26] mm/mm2; p = 0.003)。输注红细胞可显著减少血流异质性指数(从0.51 [0.34-0.62]到0.16 [0.04-0.29]; p < 0.001)。输血与其他大血管和微血管参数的变化无关。输注后微血管灌注的变化与基线微血管灌注呈负相关。

结果表明,输注红细胞可以改善失血性休克患者的舌下微循环,独立于大循环和血红蛋白水平。输注后微血管灌注的变化与基线微血管灌注呈负相关。评估微循环灌注是优化微血管灌注的关键,并确定心血管复苏过程中哪些患者可以受益于红细胞输注。

原始出处:

Tanaka, Sebastien,et al.Effect of RBC Transfusion on Sublingual Microcirculation in Hemorrhagic Shock Patients: A Pilot Study.Critical Care Medicine.September 15, 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085319, encodeId=60842085319c7, content=<a href='/topic/show?id=a3ff443092f' target=_blank style='color:#2F92EE;'>#失血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44309, encryptionId=a3ff443092f, topicName=失血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Nov 13 20:37:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718638, encodeId=2f8a1e18638d7, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Sat Sep 30 02:37:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994170, encodeId=61ee19941e0af, content=<a href='/topic/show?id=0fcb4431056' target=_blank style='color:#2F92EE;'>#失血性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44310, encryptionId=0fcb4431056, topicName=失血性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Thu Jun 15 16:37:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281941, encodeId=2817128194114, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522656, encodeId=684115226562c, content=<a href='/topic/show?id=4c364430828' target=_blank style='color:#2F92EE;'>#失血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44308, encryptionId=4c364430828, topicName=失血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c011466504, createdName=daviiliu, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607152, encodeId=304c160e1525c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=)]
    2016-11-13 yyj062
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085319, encodeId=60842085319c7, content=<a href='/topic/show?id=a3ff443092f' target=_blank style='color:#2F92EE;'>#失血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44309, encryptionId=a3ff443092f, topicName=失血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Nov 13 20:37:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718638, encodeId=2f8a1e18638d7, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Sat Sep 30 02:37:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994170, encodeId=61ee19941e0af, content=<a href='/topic/show?id=0fcb4431056' target=_blank style='color:#2F92EE;'>#失血性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44310, encryptionId=0fcb4431056, topicName=失血性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Thu Jun 15 16:37:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281941, encodeId=2817128194114, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522656, encodeId=684115226562c, content=<a href='/topic/show?id=4c364430828' target=_blank style='color:#2F92EE;'>#失血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44308, encryptionId=4c364430828, topicName=失血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c011466504, createdName=daviiliu, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607152, encodeId=304c160e1525c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085319, encodeId=60842085319c7, content=<a href='/topic/show?id=a3ff443092f' target=_blank style='color:#2F92EE;'>#失血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44309, encryptionId=a3ff443092f, topicName=失血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Nov 13 20:37:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718638, encodeId=2f8a1e18638d7, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Sat Sep 30 02:37:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994170, encodeId=61ee19941e0af, content=<a href='/topic/show?id=0fcb4431056' target=_blank style='color:#2F92EE;'>#失血性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44310, encryptionId=0fcb4431056, topicName=失血性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Thu Jun 15 16:37:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281941, encodeId=2817128194114, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522656, encodeId=684115226562c, content=<a href='/topic/show?id=4c364430828' target=_blank style='color:#2F92EE;'>#失血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44308, encryptionId=4c364430828, topicName=失血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c011466504, createdName=daviiliu, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607152, encodeId=304c160e1525c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085319, encodeId=60842085319c7, content=<a href='/topic/show?id=a3ff443092f' target=_blank style='color:#2F92EE;'>#失血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44309, encryptionId=a3ff443092f, topicName=失血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Nov 13 20:37:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718638, encodeId=2f8a1e18638d7, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Sat Sep 30 02:37:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994170, encodeId=61ee19941e0af, content=<a href='/topic/show?id=0fcb4431056' target=_blank style='color:#2F92EE;'>#失血性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44310, encryptionId=0fcb4431056, topicName=失血性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Thu Jun 15 16:37:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281941, encodeId=2817128194114, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522656, encodeId=684115226562c, content=<a href='/topic/show?id=4c364430828' target=_blank style='color:#2F92EE;'>#失血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44308, encryptionId=4c364430828, topicName=失血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c011466504, createdName=daviiliu, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607152, encodeId=304c160e1525c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=)]
    2016-10-17 kord1982
  5. [GetPortalCommentsPageByObjectIdResponse(id=2085319, encodeId=60842085319c7, content=<a href='/topic/show?id=a3ff443092f' target=_blank style='color:#2F92EE;'>#失血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44309, encryptionId=a3ff443092f, topicName=失血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Nov 13 20:37:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718638, encodeId=2f8a1e18638d7, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Sat Sep 30 02:37:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994170, encodeId=61ee19941e0af, content=<a href='/topic/show?id=0fcb4431056' target=_blank style='color:#2F92EE;'>#失血性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44310, encryptionId=0fcb4431056, topicName=失血性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Thu Jun 15 16:37:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281941, encodeId=2817128194114, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522656, encodeId=684115226562c, content=<a href='/topic/show?id=4c364430828' target=_blank style='color:#2F92EE;'>#失血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44308, encryptionId=4c364430828, topicName=失血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c011466504, createdName=daviiliu, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607152, encodeId=304c160e1525c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=)]
    2016-10-17 daviiliu
  6. [GetPortalCommentsPageByObjectIdResponse(id=2085319, encodeId=60842085319c7, content=<a href='/topic/show?id=a3ff443092f' target=_blank style='color:#2F92EE;'>#失血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44309, encryptionId=a3ff443092f, topicName=失血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Sun Nov 13 20:37:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718638, encodeId=2f8a1e18638d7, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Sat Sep 30 02:37:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994170, encodeId=61ee19941e0af, content=<a href='/topic/show?id=0fcb4431056' target=_blank style='color:#2F92EE;'>#失血性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44310, encryptionId=0fcb4431056, topicName=失血性休克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Thu Jun 15 16:37:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281941, encodeId=2817128194114, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522656, encodeId=684115226562c, content=<a href='/topic/show?id=4c364430828' target=_blank style='color:#2F92EE;'>#失血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44308, encryptionId=4c364430828, topicName=失血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c011466504, createdName=daviiliu, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607152, encodeId=304c160e1525c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 17 06:37:00 CST 2016, time=2016-10-17, status=1, ipAttribution=)]

相关资讯

Crit Care:心脏手术后谵妄的危险因素分析

目前对心脏手术后谵妄的危险因素还不能完全的理解。本研究的目的是调查术中病理生理改变和治疗干预措施对术后谵妄风险的影响。 这项回顾性队列研究在一所大学医院的心脏外科ICU中进行,纳入了心脏手术后的2个月期间的患者。使用经验证的评分对谵妄进诊断。使用非参数检验对有或无谵妄患者进行比较,应用逻辑回归分析确定独立危险因素。 在心脏手术后的194例患者中,有50例(26%)在他们的住院期间出现了

Circulation子刊:PCI治疗急性冠脉综合征患者输血和急性肾损伤的危险性分析

由此可见,输血与接受PCI治疗的急性冠状动脉综合征患者的AKI发生密切相关,需要进一步的研究来确定是否限制性输血策略可能通过降低AKI风险改善PCI的预后。

Ann Surg:围手术期输血不利于结肠癌术后的生存

目的:探讨输血和脓毒症对结肠癌术后患者的结肠癌疾病特异性生存率、心血管疾病特异性生存率和总体生存率的潜在作用。背景:通过全身炎症反应,围手术期输血与感染性并发症和癌症复发风险的增加有关。此外,最近的研究表明,脓毒症、全身性炎症反应和不良心血管结局之间存在关联。然而,目前没有关于输血、脓毒症和术后疾病特异性生存率之间的相关性研究。方法:纳入了2004-2011年纽约国家癌症登记处和全州规划研究合作系

2015NICE指南——输血(NG.24)发布

2015年11月,英国国家卫生与临床优化研究所 (NICE)发布了输血指南。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载)

男子肝脏碎成豆腐渣,靠全身换血才救回一命

因为一场意外,湖南岳阳男子王师傅的肝脏碎成了“豆腐渣”,生命垂危。所幸送医及时,医生奋力抢救,为他换了一身血,王师傅这才捡回一条命。 回想起丈夫遭遇的意外,陈女士仍心有余悸。据悉,王师傅是湖南岳阳人,刚刚举家搬到长沙,从事废品回收生意。刚稳定下来没多久,王师傅就遭遇了一场厄运。陈女士介绍称,事情发生在几天前,丈夫准备把一台16吨重的报废装载机进行拆解后回收,于是专门请了一辆随车吊协助拆卸

全球输血治疗衰老临床试验进行中,硅谷大神彼得·蒂尔充满期待

如果一切进展顺利的话,全世界首个利用年轻人的血液「治疗」衰老的临床试验,已经在美国加利福尼亚州蒙特雷市的某个门诊开始了。这是人类以另一种方式再一次向「永生」出击,只不过这一次的临床研究会让人感到一丝丝「不安」。尤其是在Inc爆料美国著名企业家与风险资本家、PayPal联合创始人彼得·蒂尔(Peter Thiel)对此事表现出极大的兴趣,似乎很有兴趣尝试这种治疗,于是人们开始反思关于「永生」的一